Aliases:This biomarker is also known as:
- Short-chain type dehydrogenase/reductase XH98G2,
- Mitochondrial ribonuclease P protein 2,
- amyloid-beta peptide binding alcohol dehydrogenase,
- AB-binding alcohol dehydrogenase,
- mitochondrial RNase P subunit 2,
- EC 126.96.36.199,EC 188.8.131.52,
- short chain type dehydrogenase/reductase XH98G2,
- Type II HADH,
- 3-hydroxyacyl-CoA dehydrogenase type II,
- hydroxysteroid (17-beta) dehydrogenase 10,
- 17-beta-hydroxysteroid dehydrogenase 10,
- short chain L-3-hydroxyacyl-CoA dehydrogenase type 2,
- mental retardation, X-linked, syndromic 10,
- 3-hydroxyacyl-CoA dehydrogenase type-2,
- short chain dehydrogenase/reductase family 5C, member 1,
- 3-hydroxy-2-methylbutyryl-CoA dehydrogenase,
- hydroxyacyl-Coenzyme A dehydrogenase, type II, hydroxyacyl-Coenzyme A dehydrogenase, type II,
- Mitochondrial RNase P protein 2,
- mitochondrial ribonuclease P protein 2,
- 17-beta-HSD 10,
- endoplasmic reticulum-associated amyloid beta-peptide-binding protein,
- Endoplasmic reticulum-associated amyloid beta-peptide-binding protein,
HSD17B10, hydroxysteroid (17-beta) dehydrogenase 10, is a member of the short-chain dehydrogenase/reductase superfamily. HSD17B10 functions in mitochondrial tRNA maturation and catalyzes the oxidation of a wide variety of fatty acids, alcohols, and steroids. The protein is thought to play a role in the development of Alzheimer's disease. There are several alternatively spliced transcript variants, of which only two have been fully sequenced.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
No additional breast data is available.
HSD17B10 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.